argenex (NASDAQ:ARGX) Given New $1,120.00 Price Target at Guggenheim

argenex (NASDAQ:ARGX) had its price objective reduced by Guggenheim from $1,160.00 to $1,120.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts also recently issued research reports about the stock. Truist Financial increased their price target on shares of argenex from $950.00 to $1,030.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Morgan Stanley lifted their price objective on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research report on Thursday, December 4th. Robert W. Baird lowered shares of argenex from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 18th. Piper Sandler upped their price objective on shares of argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Evercore lifted their price target on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $999.22.

argenex Trading Down 0.6%

Shares of NASDAQ ARGX opened at $766.92 on Friday. The firm has a fifty day simple moving average of $826.36 and a two-hundred day simple moving average of $810.76. The firm has a market capitalization of $47.46 billion, a PE ratio of 39.29, a price-to-earnings-growth ratio of 0.67 and a beta of 0.37. argenex has a 12 month low of $510.05 and a 12 month high of $934.62.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. The company had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. argenex had a net margin of 30.42% and a return on equity of 63.59%. On average, sell-side analysts predict that argenex will post 3.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new position in shares of argenex in the fourth quarter valued at approximately $5,080,000. Dorsey Wright & Associates bought a new position in argenex during the 4th quarter worth $1,244,000. Compound Planning Inc. lifted its holdings in shares of argenex by 120.7% during the fourth quarter. Compound Planning Inc. now owns 1,302 shares of the company’s stock worth $1,095,000 after buying an additional 712 shares in the last quarter. Invesco Ltd. boosted its position in shares of argenex by 390.4% in the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after acquiring an additional 331,489 shares during the period. Finally, Corient Private Wealth LLC boosted its position in shares of argenex by 12,441.8% in the fourth quarter. Corient Private Wealth LLC now owns 246,572 shares of the company’s stock valued at $207,355,000 after acquiring an additional 244,606 shares during the period. 60.32% of the stock is owned by institutional investors.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.